Beijing Health & Biotech Co., Ltd. announced that it will receive CNY 270,000,000 in an equity round of funding on December 1, 2014. The transaction will include participation from new investor, Xi'an Kaiyuan Investment Group Co., Ltd. The company will receive CNY 254,117,600 as part of the cash capital increase and CNY 15,882,400 as part of a share transfer. As part of the share transfer, the investor will acquire 2% stake in the company.

As part of the transaction, CNY 5,203,100 will be transferred to the registered capital of the company and the balance will be transferred to its reserve. The company will receive the funding in two tranches with the first tranche of CNY 177,882,320 within 10 working days upon effective of the contract and the second installment will be received within 12 months upon the 1st installment payment. Pursuant to completion of the transaction, the registered capital of the company will increase from CNY 11,056,500 to CNY 16,259,600.

The investor in total will acquire 34% stake in the company. The transaction was approved at the 17th meeting of 9th board of directors of Xi'an Kaiyuan Investment Group Co., Ltd. The transaction is not subject to approval from the shareholders of the investor. Xigema Certified Public Accountants (Special General Partnership) acted as an audit institution to the company for the transaction.

The company reported revenues of CNY 33,451,195.89, operating loss of CNY 18,997,452.53, total loss of CNY 15,718,122.47, and net loss of CNY 15,718,127.74 for the year ended December 31, 2013.